✦ LIBER ✦

A092 RMPT in Relapsed/Refractory Multiple Myeloma: Results of a Multicenter Phase II Clinical Trial

✍ Scribed by Palumbo, A; Larocca, A; Sanpaolo, G; Falcone, AP; Federico, V; Canepa, L; Crugnola, M; Baldini, L; Magarotto, V; Falco, P; Petrucci, MT; Boccadoro, M

Book ID: 118629231
Publisher: CIG Media Group, LP.
Year: 2009
Tongue: English
Weight: 111 KB
Volume: 9
Category: Article
ISSN: 1557-9190
DOI: 10.1016/s1557-9190(11)70458-9

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Phase II trial of temsirolimus in patien

Phase II trial of temsirolimus in patients with relapsed or refractory multiple myeloma

✍ Sherif S. Farag; Shuhong Zhang; Buffy S. Jansak; Xiaojing Wang; Eric Kraut; Kenn 📂 Article 📅 2009 🏛 Elsevier Science 🌐 English ⚖ 508 KB

In a phase II trial, 16 patients with relapsed refractory multiple myeloma received temsirolimus 25mg I.V. weekly until progression. One partial response and 5 minor responses were observed for a total response rate of 38%. The median time to progression was 138 days. Grade 3-4 toxicity included fat

Extended follow-up of a phase II trial i

Extended follow-up of a phase II trial in relapsed, refractory multiple myeloma: : Final time-to-event results from the SUMMIT trial

✍ Paul G. Richardson; Bart Barlogie; James Berenson; Seema Singhal; Sundar Jaganna 📂 Article 📅 2006 🏛 John Wiley and Sons 🌐 English ⚖ 123 KB 👁 2 views

A584 Preliminary Results of a Phase I Tr

A584 Preliminary Results of a Phase I Trial of Intravenous MV-NIS for Relapsed/Refractory Multiple Myeloma

✍ Tong, C; Russell, SJ; Lacy, MQ; Federspiel, M; Griesmann, G; Gertz, MA; Lowe, V; 📂 Article 📅 2009 🏛 CIG Media Group, LP. 🌐 English ⚖ 84 KB

Clinical experience with thalidomide in

Clinical experience with thalidomide in multiple myeloma: Phase II trial results in refractory disease and ongoing studies

✍ Nikhil C Munshi; K.R Desikan; Bart Barlogie 📂 Article 📅 2000 🏛 Elsevier Science 🌐 English ⚖ 649 KB

Phase II randomized trial of bevacizumab

Phase II randomized trial of bevacizumab versus bevacizumab and thalidomide for relapsed/refractory multiple myeloma: a California Cancer Consortium trial

✍ George Somlo; Ashkan Lashkari; William Bellamy; Todd M. Zimmerman; Joseph M. Tus 📂 Article 📅 2011 🏛 John Wiley and Sons 🌐 English ⚖ 88 KB

A systematic review of phase-II trials o

A systematic review of phase-II trials of thalidomide monotherapy in patients with relapsed or refractory multiple myeloma

✍ Axel Glasmacher; Corinna Hahn; Florian Hoffmann; Ralph Naumann; Hartmut Goldschm 📂 Article 📅 2006 🏛 John Wiley and Sons 🌐 English ⚖ 181 KB